Small molecule protein kinase inhibitors targeting tyrosine kinases, including epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), have been widely used to improve the prognosis of advanced NSCLC patients with genetic alterations in these targeted genes [2, 3]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.